RE: Lancet - My key observations13 Nov 2020 00:00
And the competition is poor:
Currently, treatment options for COVID-19 remain limited, with the only evidence-based therapies being remdesivir and dexamethasone.3, 4 Despite the use of these therapies, clinical outcomes remain poor.